|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
TTF-1 and napsin A for lung adenocarcinoma, p40 for squamous lung cancer, GATA3 and mammaglobin for breast cancer, or synaptophysin and chromogranin A for neuroendocrine tumors).
|
30354850 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results of this study indicated that p38 α and EGFR might play an important role in the development and growth of lung cancer and might be a potential therapeutic target for the treatment of lung cancer.
|
30827261 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, results showed that alantolactone could activate p38 MAPK pathway and suppress NF-κB pathway, which are involving in lung cancer development.
|
31489665 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Autophagy Regulated by Gain of Function Mutant p53 Enhances Proteasomal Inhibitor-Mediated Cell Death through Induction of ROS and ERK in Lung Cancer Cells.
|
30723502 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, morphology and TTF-1 and p40 IHC staining is sufficient for correct diagnosis in most non-small cell lung cancers.
|
30718697 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Functional rescue experiment was performed by adding MAPK-specific activator P79350 to A549 cells with si-ACP5 to measure the effects of ERK/MAPK axis on LC progression.
|
31650885 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the present findings indicated that Cd induced A549 cell migration and invasion by activating ERK, and it was hypothesized that p-ERK could serve as a target in the clinical treatment of Cd-induced lung cancer.
|
31410139 |
2019 |
|
ovarian neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we systematically evaluated the extent of MEK/ERK pathway activation and efficacy of pathway inhibition in a large panel of well-annotated HGSOC patient-derived xenograft models.
|
30679390 |
2019 |
|
ovarian neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Linc00161 regulated the drug resistance of ovarian cancer via modulating microRNA-128/MAPK1.
|
30556928 |
2019 |
|
ovarian neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
LAMC2 regulated by microRNA-125a-5p accelerates the progression of ovarian cancer via activating p38 MAPK signalling.
|
31301414 |
2019 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
LAMC2 regulated by microRNA-125a-5p accelerates the progression of ovarian cancer via activating p38 MAPK signalling.
|
31301414 |
2019 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Linc00161 regulated the drug resistance of ovarian cancer via modulating microRNA-128/MAPK1.
|
30556928 |
2019 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we systematically evaluated the extent of MEK/ERK pathway activation and efficacy of pathway inhibition in a large panel of well-annotated HGSOC patient-derived xenograft models.
|
30679390 |
2019 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As tumor cells showed positive immunostaining for p40 and CK5/6, the immunophenotype of the tumor was consistent with squamous cell carcinoma (SCC).
|
30216599 |
2018 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytokeratin 5/6 (CK5/6), p63, and p40 are commonly used as immunohistochemical markers for squamous cell carcinoma (SqCC) of the lung.
|
30546464 |
2018 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Psoriasin overexpression confers drug resistance to cisplatin by activating ERK in gastric cancer.
|
29956751 |
2018 |
|
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
It was determined that TIPE2 inhibited GC cell proliferation mainly by reducing the expression of phosphorylated AKT and ERK, which caused subsequent inhibition of the PI3K‑AKT and Ras‑Raf‑MEK‑ERK1/2 signaling pathways.
|
30015980 |
2018 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
The mechanism elucidation concerning the ERK1/2 and p38 kinases and transcription factor c-jun/AP-1 might contribute another idea to the development of chemotherapy strategy for the gastric cancers in the future.
|
30011079 |
2018 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, our data demonstrated that miR‑454 may play tumour‑suppressing roles in GC through the regulation of MAPK1, suggesting that miR‑454 may be a novel biomarker and therapeutic target for patients with this disease.
|
29286172 |
2018 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increasing HER2 α2,6 sialylation facilitates gastric cancer progression and resistance via the Akt and ERK pathways.
|
30226606 |
2018 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
MicroRNA-585 suppresses tumor proliferation and migration in gastric cancer by directly targeting MAPK1.
|
29550487 |
2018 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additionally, lncRNA GAPLINC promoted the expression of MAPK1 and the enhancement of GC cell proliferation and cell cycle progression by LncRNA GAPLINC was dependent on MAPK1 in vitro and in vivo.
|
29785127 |
2018 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Overexpression of MAPK1 in the PC3 cells increased the tumorigenicity and metastasis.
|
30078000 |
2018 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer.
|
29315556 |
2018 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
CCL17-CCR4 axis promotes metastasis via ERK/MMP13 pathway in bladder cancer.
|
30230587 |
2018 |